JP2021501150A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021501150A5 JP2021501150A5 JP2020523323A JP2020523323A JP2021501150A5 JP 2021501150 A5 JP2021501150 A5 JP 2021501150A5 JP 2020523323 A JP2020523323 A JP 2020523323A JP 2020523323 A JP2020523323 A JP 2020523323A JP 2021501150 A5 JP2021501150 A5 JP 2021501150A5
- Authority
- JP
- Japan
- Prior art keywords
- pembrolizumab
- administered
- pharmaceutical composition
- antigen
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229960002621 pembrolizumab Drugs 0.000 claims 45
- 239000008194 pharmaceutical composition Substances 0.000 claims 26
- 239000000427 antigen Substances 0.000 claims 21
- 102000036639 antigens Human genes 0.000 claims 21
- 108091007433 antigens Proteins 0.000 claims 21
- 239000012634 fragment Substances 0.000 claims 21
- 206010028980 Neoplasm Diseases 0.000 claims 10
- 201000011510 cancer Diseases 0.000 claims 7
- 238000011319 anticancer therapy Methods 0.000 claims 6
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 6
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 6
- 238000011272 standard treatment Methods 0.000 claims 6
- 230000009885 systemic effect Effects 0.000 claims 6
- 201000007270 liver cancer Diseases 0.000 claims 4
- 208000014018 liver neoplasm Diseases 0.000 claims 4
- 206010006187 Breast cancer Diseases 0.000 claims 3
- 206010052360 Colorectal adenocarcinoma Diseases 0.000 claims 3
- 208000006265 Renal cell carcinoma Diseases 0.000 claims 3
- 201000008274 breast adenocarcinoma Diseases 0.000 claims 3
- 238000002648 combination therapy Methods 0.000 claims 3
- 201000006972 gastroesophageal adenocarcinoma Diseases 0.000 claims 3
- 201000001441 melanoma Diseases 0.000 claims 3
- 206010041823 squamous cell carcinoma Diseases 0.000 claims 3
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 2
- 208000030808 Clear cell renal carcinoma Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010027476 Metastases Diseases 0.000 claims 1
- 206010073251 clear cell renal cell carcinoma Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 230000009401 metastasis Effects 0.000 claims 1
- 201000011330 nonpapillary renal cell carcinoma Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762578071P | 2017-10-27 | 2017-10-27 | |
| US62/578,071 | 2017-10-27 | ||
| PCT/US2018/057731 WO2019084418A1 (en) | 2017-10-27 | 2018-10-26 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF LIVER CANCER |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021501150A JP2021501150A (ja) | 2021-01-14 |
| JP2021501150A5 true JP2021501150A5 (https=) | 2021-12-02 |
Family
ID=64453576
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020523323A Pending JP2021501150A (ja) | 2017-10-27 | 2018-10-26 | 肝臓がんを治療するための組成物及び方法 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20200353022A1 (https=) |
| EP (1) | EP3700544A1 (https=) |
| JP (1) | JP2021501150A (https=) |
| KR (1) | KR20200078483A (https=) |
| CN (1) | CN111278448A (https=) |
| AR (1) | AR113805A1 (https=) |
| AU (1) | AU2018355519A1 (https=) |
| BR (1) | BR112020007494A2 (https=) |
| CA (1) | CA3075294A1 (https=) |
| MX (1) | MX2020003388A (https=) |
| SG (1) | SG11202002123XA (https=) |
| TW (1) | TWI817958B (https=) |
| WO (1) | WO2019084418A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20131167T1 (hr) | 2007-06-18 | 2014-01-03 | Merck Sharp & Dohme B.V. | Antitijela za humani receptor programirane smrti pd-1 |
| US12310999B2 (en) * | 2017-04-28 | 2025-05-27 | Merck Sharp & Dohme Corp. | Biomarkers for cancer therapeutics |
| CN114191547A (zh) * | 2021-12-23 | 2022-03-18 | 中山大学 | 仑伐替尼与pd-1单抗联用在制备抗肝癌药物中的应用 |
| WO2025085538A1 (en) * | 2023-10-17 | 2025-04-24 | Lanier Biotherapeutics, Inc. | Alarmin binding molecules and treatment of cancer |
| WO2025211692A1 (ko) * | 2024-04-02 | 2025-10-09 | (주)에트노바테라퓨틱스 | 암 예방 또는 치료를 위한 병용 투여용 약학 조성물 세트 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| DE60115600T2 (de) | 2000-01-21 | 2006-07-20 | Biovex Ltd. | Virusstämme für die onkolytische behandlung von krebs |
| HRP20131167T1 (hr) | 2007-06-18 | 2014-01-03 | Merck Sharp & Dohme B.V. | Antitijela za humani receptor programirane smrti pd-1 |
| ES2676205T3 (es) | 2011-03-31 | 2018-07-17 | Merck Sharp & Dohme Corp. | Formulaciones estables de anticuerpos para el receptor PD-1 humano de muerte programada y tratamientos relacionados |
| JP6457940B2 (ja) | 2012-08-30 | 2019-01-23 | アムジエン・インコーポレーテツド | 単純ヘルペスウイルスおよび免疫チェックポイント阻害薬を使用して、メラノーマを治療するための方法 |
| DK3169341T3 (da) * | 2014-07-16 | 2019-08-05 | Transgene Sa | Onkolytisk virus til ekspression af immun-checkpoint-modulatorer |
| AU2015289081B2 (en) * | 2014-07-16 | 2020-02-06 | Transgene Sa | Combination of oncolytic virus with immune checkpoint modulators |
| US10751412B2 (en) | 2015-05-29 | 2020-08-25 | Merck Sharp & Dohme Corp. | Combination of a PD-1 antagonist and CPG-C type oligonucleotide for treating cancer |
| PL3426271T3 (pl) * | 2016-03-10 | 2025-11-24 | Cg Oncology, Inc. | Sposoby leczenia guzów litych terapią skojarzoną |
| WO2018111902A1 (en) * | 2016-12-12 | 2018-06-21 | Multivir Inc. | Methods and compositions comprising viral gene therapy and an immune checkpoint inhibitor for treatment and prevention of cancer and infectious diseases |
| US12310999B2 (en) * | 2017-04-28 | 2025-05-27 | Merck Sharp & Dohme Corp. | Biomarkers for cancer therapeutics |
-
2018
- 2018-10-26 CA CA3075294A patent/CA3075294A1/en active Pending
- 2018-10-26 BR BR112020007494-2A patent/BR112020007494A2/pt not_active IP Right Cessation
- 2018-10-26 SG SG11202002123XA patent/SG11202002123XA/en unknown
- 2018-10-26 MX MX2020003388A patent/MX2020003388A/es unknown
- 2018-10-26 US US16/759,476 patent/US20200353022A1/en not_active Abandoned
- 2018-10-26 AU AU2018355519A patent/AU2018355519A1/en not_active Abandoned
- 2018-10-26 WO PCT/US2018/057731 patent/WO2019084418A1/en not_active Ceased
- 2018-10-26 EP EP18807758.0A patent/EP3700544A1/en not_active Withdrawn
- 2018-10-26 CN CN201880068853.5A patent/CN111278448A/zh active Pending
- 2018-10-26 JP JP2020523323A patent/JP2021501150A/ja active Pending
- 2018-10-26 KR KR1020207008272A patent/KR20200078483A/ko not_active Ceased
- 2018-10-26 AR ARP180103133A patent/AR113805A1/es unknown
- 2018-10-29 TW TW107138162A patent/TWI817958B/zh not_active IP Right Cessation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021501150A5 (https=) | ||
| JP2019527706A5 (https=) | ||
| Palumbo et al. | Systemic cancer therapy: achievements and challenges that lie ahead | |
| JP2021063120A5 (https=) | ||
| JP2016520082A5 (https=) | ||
| JP2020515637A5 (https=) | ||
| JP2022088662A5 (https=) | ||
| JP2019501204A5 (https=) | ||
| IL292193B2 (en) | Anti-b7-h1 antibodies for treating tumors | |
| IL276515B1 (en) | PD–L1-specific antibodies and methods of using them | |
| Koning et al. | Toxicity of concurrent radiochemotherapy for locally advanced non–small-cell lung cancer: a systematic review of the literature | |
| RU2016146993A (ru) | Комбинация антитела к CCR4 и агониста 4-1BB для лечения рака | |
| RU2017117664A (ru) | Комбинация | |
| JP2019504105A5 (https=) | ||
| RU2016148645A (ru) | Антитела к в7-н1 и к ctlа-4 для лечения немелкоклеточного рака легкого | |
| JP2018521135A5 (https=) | ||
| JP2021511372A5 (https=) | ||
| CN112888458A (zh) | Cldn18的抗体和化疗药物的联合治疗 | |
| JP2017514800A5 (https=) | ||
| Inohara et al. | Phase 2 study of docetaxel, cisplatin, and concurrent radiation for technically resectable stage III-IV squamous cell carcinoma of the head and neck | |
| Ding et al. | Immunotherapy-based novel nanoparticles in the treatment of gastrointestinal cancer: trends and challenges | |
| Buss et al. | Nano-BCG: a promising delivery system for treatment of human bladder cancer | |
| JP2018513155A5 (https=) | ||
| RU2018101722A (ru) | Днк-вакцина, нацеленная на vegfr-2, для комбинированной терапии | |
| Ho et al. | Cancer Management by Tyrosine Kinase Inhibitors: Efficacy |